Fig. 2.

Tree diagram showing the distribution of patients across different subsets of CICIL analyses. Analyses on different subsets of patients were performed: (i) all patients, (ii) all patients receiving cetuximab either as monotherapy or in combination (cetuximab arm), and (iii) KRASwt patients receiving cetuximab. All APEC patients were KRASwt. *Not all patients were able to enter the CICIL analysis. Those without more than one tumor size (TS) assessment or with missing organ information were excluded